Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T-19 for Relapsed/Refractory B-ALL in Patients <25 Years
NCT05270772Phase 1Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2021
- Primary completion
- Jul 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ARI-0001 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Chinese PLA General Hospital. Primary endpoints: Dose Limiting Toxicity at 2 years, Maximum Tolerated Dose at 2 years and 1 more. Status: unknown.
02
Drugs
ARI-0001
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05270772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270772.